Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity
Open Access
- 1 January 2020
- journal article
- research article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 10 (4) , 1678-1693
Abstract
Prostate-specific membrane antigen (PSMA)-targeted radioligands have been used for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Recently, albumin-binding PSMA radioligands with enhanced blood circulation were developed to increase the tumor accumulation of activity. The present study aimed at the design, synthesis and preclinical evaluation of a novel class of PSMA-targeting radioligands equipped with ibuprofen as a weak albumin-binding entity in order to improve the pharmacokinetic properties.Keywords
This publication has 39 references indexed in Scilit:
- Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin BindingTheranostics, 2016
- 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human StudiesJournal of Nuclear Medicine, 2015
- Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate CancerJournal of Nuclear Medicine, 2015
- The structure of ibuprofen bound to cyclooxygenase-2Journal of Structural Biology, 2015
- DOTA Conjugate with an Albumin-Binding Entity Enables the First Folic Acid–Targeted 177Lu-Radionuclide Tumor Therapy in MiceJournal of Nuclear Medicine, 2012
- Spectroscopic investigation of the interaction of the toxicant, 2‐naphthylamine, with bovine serum albuminJournal of Biochemical and Molecular Toxicology, 2011
- A Portable Albumin Binder from a DNA‐Encoded Chemical LibraryAngewandte Chemie International Edition, 2008
- Tissue-specificity of prostate specific antigens: Comparative analysis of transcript levels in prostate and non-prostatic tissuesCancer Letters, 2006
- Structural Basis of the Drug-binding Specificity of Human Serum AlbuminJournal of Molecular Biology, 2005
- Characterizing a Drug’s Primary Binding Site on AlbuminJournal of Pharmaceutical Sciences, 2003